17 beta-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study

• Type of Material: Article
• Authors: Lindsay J Collin, Emory University; Sinna P Ulrichsen, Aarhus University Hospital; Thomas P Ahern, University of Vermont; Michael Goodman, Emory University; Lauren McCullough, Emory University; Lance Waller, Emory University; Kristina Bang Christensen, Aarhus University Hospital; Per Damkier, Odense University Hospital; Stephen Hamilton-Dutoit, Aarhus University Hospital; Kristina L Lauridsen, Aarhus University Hospital; Rami Yacoub, Emory University; Peer M Christiansen, Aarhus University Hospital; Bent Ejlertsen, Danish Breast Canc Grp; Henrik T Sorensen, Aarhus University Hospital; Deirdre P Cronin-Fenton, Aarhus University Hospital; Timothy Lash, Emory University
• Language: English
• Date: 2019-10-30
• Publisher: TAYLOR & FRANCIS LTD
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2019 Acta Oncologica Foundation
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1080/0284186X.2019.1684560
• Title of Journal or Parent Work: ACTA ONCOLOGICA
• Volume: 59
• Issue: 3
• Start Page: 329
• End Page: 333
• Grant/Funding Information: This project was supported by funding from the National Cancer Institute (F31CA239566) awarded to Lindsay J. Collin, (R01 CA118708 and R01 CA166825) awarded to Timothy L. Lash, the Danish Cancer Society (DP06117) awarded to Stephen Hamilton-Dutoit, the Lundbeck Foundation (R167-2013-15861) awarded to Deirdre Cronin-Fenton, the Danish Medical Research Council (DOK 1158869) awarded to Timothy L. Lash, the Karen Elise Jensen Foundation awarded to Henrik Toft Sørensen, and the Program for Clinical Research Infrastructure established by the Lundbeck and the Novo Nordisk Foundations awarded to Henrik Toft Sørensen. Thomas P. Ahern was supported by an award from the National Institute for General Medical Studies (P20 GM103644).
• Keywords: TAMOXIFEN; Science & Technology; COOPERATIVE GROUP DBCG; ESTRADIOL; DEHYDROGENASES; ESTROGEN; ENDOCRINE THERAPY; Life Sciences & Biomedicine; PREDICTS; EXPRESSION; Oncology; TYPE-1

Abstract

Approximately 20–40% of patients diagnosed with breast cancer will experience a recurrence up to 20 years after their original diagnosis. 17?-hydroxysteroid dehydrogenase 1 and 2 (HSD17B1 and HSD17B2, respectively) regulate intratumoral concentrations of oestradiol, which promotes growth and proliferation of hormone dependent tumours. Breast carcinomas with increased HSD17B1, without a corresponding increase in HSD17B2, expression may become resistant to tamoxifen therapy by producing locally higher concentrations of oestradiol, which compete with tamoxifen and its metabolites for binding to the oestrogen receptor (ER).